SOFTX SoftOx Solutions AS

OSL · NO · Healthcare · Biotechnology · soft-ox.com

0.1280NOK-1.39%Mkt Cap: 31.83M $P/E: —Today

SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that anti-infective therapy for airway infections in Norway. The company develops SIS-03, a lead clinical program t…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap31.83M USD

Enterprise Value29.57M USD

Revenue (TTM)1.30M USD

Gross Profit1.30M USD

Net Income (TTM)-1.01M USD

Revenue/Share0.0050 NOK

Last Price0.1280 NOK

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees2

CountryNO

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA-16.14

EV/Revenue22.78

P/S24.87

P/B12.98

EPS (TTM)-0.01

EPS (Forward)—

52W Range

0.049068% of range0.1658

52W High0.1658 NOK

52W Low0.0490 NOK

Profitability

Gross Margin100.00%

Oper. Margin-447.27%

EBITDA Margin-141.16%

Profit Margin-165.83%

ROE-47.11%

ROA-31.87%

Growth

Revenue Growth-55.60%

Earnings Growth—

Cash Flow & Leverage

Operating CF-1.76M USD

CapEx (TTM)—

FCF Margin-150.59%

FCF Yield-6.14%

Net Debt-2.00M USD

Net Debt/EBITDA1.09

Balance Sheet

Debt/Equity0.45

Current Ratio4.21

Quick Ratio4.21

Book Value/Sh0.01 NOK

Cash/Share0.0080 NOK

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 NOK

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Splits

Last Split50:1

Split DateJul 2, 2018

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.2.66B

Float1.64B

Insiders38.91%

Institutions5.92%

Technical

SMA 500.1026 (+24.7%)

SMA 2000.0932 (+37.3%)

Beta0.96

S&P 52W Chg14.58%

Avg Vol (30d)29.72M

Avg Vol (10d)46.88M

Technical Indicators

RSI (14)65.7

MACD0.0073

MACD Signal0.0070

MACD Hist.+0.0003

BB Upper0.1339 NOK

BB Middle0.1201 NOK

BB Lower0.1064 NOK

BB Width22.94%

ATR (14)0.0089 NOK

Vol Ratio (20d)0.77x